FDA Adverse Event Injury Summary report: N

UNK KNEE PATELLA SIGMA

MDR report key: 14929684 · Received July 6, 2022

Report

Report Number
1818910-2022-12355
Event Type
Injury
Date Received
July 6, 2022
Date of Event
April 27, 2020
Report Date
July 6, 2022
Manufacturer
DEPUY ORTHOPAEDICS INC US
Product Code
JWH
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
CH
Reporter Occupation
OTHER HEALTH CARE PROFESSIONAL
Health Professional
Yes

Narratives

Additional Manufacturer Narrative · 0

PRODUCT COMPLAINT # (B)(4). IF INFORMATION IS OBTAINED THAT WAS NOT AVAILABLE FOR THE INITIAL MEDWATCH, A FOLLOW-UP MEDWATCH WILL BE FILED AS APPROPRIATE.

Additional Manufacturer Narrative · 0

PRODUCT COMPLAINT # : (B)(4). INVESTIGATION SUMMARY : NO DEVICE ASSOCIATED WITH THIS REPORT WAS RECEIVED FOR EXAMINATION. THIS COMPLAINT WAS OPENED TO DOCUMENT COMPLAINTS DERIVED THROUGH A JOURNAL ARTICLE REVIEW. FOLLOW-UPS WERE DONE TO TRY AND OBTAIN ADDITIONAL INFORMATION FROM THE AUTHOR OF THE JOURNAL ARTICLE. NO FURTHER INFORMATION WAS RECEIVED. DEVICE HISTORY LOT : A MANUFACTURING RECORD EVALUATION (MRE), WAS NOT POSSIBLE BECAUSE THE REQUIRED LOT CODE WAS NOT PROVIDED.

Description of Event or Problem · 0

THIS COMPLAINT IS FROM A LITERATURE SOURCE. THE FOLLOWING LITERATURE CITE HAS BEEN REVIEWED: WANG Q, TAN G, MOHAMMED A, ZHANG Y, LI D, CHEN L, KANG P. ADDING CORTICOSTEROIDS TO PERIARTICULAR INFILTRATION ANALGESIA IMPROVES THE SHORT-TERM ANALGESIC EFFECTS AFTER TOTAL KNEE ARTHROPLASTY: A PROSPECTIVE, DOUBLE-BLIND, RANDOMIZED CONTROLLED TRIAL. KNEE SURG SPORTS TRAUMATOL ARTHROSC. 2021 MAR;29(3):867-875. DOI: 10.1007/S00167-020-06039-9. EPUB 2020 MAY 2. PMID: 32361928. OBJECTIVE AND METHODS: PATIENTS RECEIVING DEPUY SIGMA FIXED-BEARING OR ROTATING-PLATFORM, POSTERIOR STABILIZED TOTAL KNEE PROSTHESES, WERE RANDOMIZED TO THE CORTICOSTEROID OR CONTROL GROUP (DOUBLE-BLINDED). THE PATIENTS IN THE CORTICOSTEROID GROUP RECEIVED A PERIARTICULAR INFILTRATION OF AN ANALGESIC COCKTAIL OF ROPIVACAINE, EPINEPHRINE, AND DEXAMETHASONE. DEXAMETHASONE WAS OMITTED FROM THE COCKTAIL IN THE CONTROL GROUP. THE PRIMARY OUTCOMES WERE POSTOPERATIVE PAIN [ASSESSED USING A VISUAL ANALOG SCALE (VAS)], TIME UNTIL THE ADMINISTRATION OF FIRST RESCUE ANALGESIA OF MORPHINE SULFATE, OVERALL MORPHINE CONSUMPTION, AND POSTOPERATIVE INFLAMMATORY BIOMARKERS [C-REACTIVE PROTEIN (CRP) AND INTERLEUKIN-6 (IL-6)]. THE SECONDARY OUTCOMES WERE FUNCTIONAL RECOVERY, ASSESSED BY THE RANGE OF KNEE MOTION, QUADRICEPS STRENGTH, AND DAILY AMBULATION DISTANCE. THE TERTIARY OUTCOMES INCLUDED POSTOPERATIVE ADVERSE EFFECTS. RESULTS: ADDING CORTICOSTEROIDS TO AN ANALGESIC COCKTAIL FOR PIA CAN MILDLY IMPROVE EARLY PAIN RELIEF AND ACCELERATE RECOVERY IN THE FIRST 24 H AFTER TOTAL KNEE ARTHROPLASTY. TERTIARY ADVERSE EVENTS (COMPLICATIONS): 32: POST-OP NAUSEA, 18: POST-OP VOMITING, 28: POST-OP WOUND SWELLING, 4: DELAYED WOUND HEALING, 3: DEEP VENOUS THROMBOSIS, 9 : CHRONIC PAIN, 2: NERVE DAMAGE (FOOT-DROP - RESOLVED WITHIN 24 HOURS).

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1162880 UNK KNEE PATELLA SIGMA KNEE PATELLA JWH DEPUY ORTHOPAEDICS INC US

Patients

Seq Age Sex Outcome Treatment
1 Unknown Required Intervention